The European Myeloma Network

A non-profit organisation created to increase understanding of multiple myeloma and to produce effective research projects and clinical trials.

Read more

EMN2025 – Athens – 10-12 April, 2025

Development

Measurable residual disease (MRD)

The most widely used tests are flow cytometry, polymerase chain reaction (PCR) and next-generation sequencing (NGS). These tests use samples of bone marrow cells (taken by aspiration) and/or peripheral blood cells (taken through a vein).

Read more

Clinical trials

EMN33 view

EMN36 view

EMN30 view

EMN28 view


View all

About the HARMONY Alliance

Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.

The HARMONY Alliance is a Public-Private Partnership for Big Data in Hematology including over 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies. HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. Various groups participate in HARMONY, including EMN. HARMONY Research Project Leads and Key Opinion Leaders in Multiple Myeloma are Prof. Pieter Sonneveld, Prof. Mario Boccadoro, and Prof. Jesus San-Miguel.

Read more

About EMN

Multiple Myeloma

Multiple myeloma is a rare and highly heterogeneous hematologic
malignancy, and the clinical research certainly plays a fundamental role in
the management of patients with this disease.

 

To deal with such a complex scenario, in 2005, a group of European
hematologists pulled together to increase their understanding of multiple
myeloma and to produce effective research projects and clinical trials.
These efforts resulted in the creation of the European Myeloma Network
(EMN), a non profit organization.

Read more

EMN Guideline Team

Various reviews, guidelines and recommendation papers are produced under the EMN umbrella. To collect & better coordinate the various proposals and manuscripts, a guideline team is in place: Monika Engelhardt from Germany, Niels van de Donk from the Netherlands, Francesca Gay from Italy and Evangelos Terpos from Greece.

Read more

Hear from the EMN President

Diversity and inclusion

Inclusion is a major value for the EMN, particularly when it comes to clinical trials. The myeloma community is in fact highly heterogeneous and the EMN strongly believes that the same high-quality treatments should be offered to any patients, regardless of their gender, race, ethnicity, sexualorientation, disability, religion, age, cultural backgrounds, life experiences, thoughts, and ideas. We are extremely grateful for the fundamental role our patients play in the EMN clinical studies, and the contribution of each one of them is equally recognized and appreciated.

Pieter Sonneveld

President

Mario Boccadoro

Vicepresident

Fredrik Schjesvold

Senior

Gordon Cook

Senior

Heinz Ludwig

Senior

Hermann Einsele

Senior

Jesus San-Miguel

Senior

Meletios Dimopoulos

Senior

Philippe Moreau

Senior

Roman Hajek

Senior

Meral Beksac

Senior

Christoph Driessen

Senior

Annemiek Broijl

President - Junior

Cyrille Touzeau

Junior

Enrique Ocio

Junior

Francesca Gay

Junior

Guldane Cengiz Seval

Junior

Jakub Radocha

Junior

Leo Rasche

Junior

Maria Gavriatopoulou

Junior

Maria Krauth

Junior

Rakesh Popat

Junior

Tobias Slordahl

Junior

News

31 January 2024

Register to the EMN2024 conference! read

03 January 2024

Last week to submit to EMN2024! read

Events

from to
Scheduled

6th EMN meeting 10-12 April 2025 – save the date! view

Scheduled

EMN17 study oral presentation at ASH 2023 view

Media

31 January 2024

EMN17 study – FDA submission read

13 December 2023

EMN17 study – ASH2023 read

11 December 2023

EMN24 study – ASH2023 read

Contact

For more information about our trials or events, you can contact us through: info@emn.life

Although we do understand sometimes it is hard to navigate the complex world of multiple myeloma, we cannot provide clinical assessments or consultations by email. Please refer to your treating physicians for any doubts, they certainly have a more complete overview of your medical history and treatments to appropriately assist you.

630-6308222_image-transparent-twitter-icon-png-png-download ... @EMN_EuMMnet

linkedin-icon | Athens GA | W&A Engineeringhttps://www.linkedin.com/company/emn-research-italy/